<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889808</url>
  </required_header>
  <id_info>
    <org_study_id>JGC-INM-2014-01</org_study_id>
    <nct_id>NCT03889808</nct_id>
  </id_info>
  <brief_title>Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.</brief_title>
  <official_title>Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study to evaluate the seroprevalence of anti-bodies against C.
      difficile toxins A and B and the asymptomatic carriage of C. difficile in IBD patients
      according to the need and type of immunosuppressive therapy. The ultimate goal is to
      identify, among IBD patients, those with the highest risk of CDI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Clostridium difficile anti-toxin Abs in patients with IBD</measure>
    <time_frame>0 days</time_frame>
    <description>Determination of serum anti-toxin Abs for C. difficile with ELISA (enzyme-linked immunosorbent assay). The concentration of C. difficile anti-toxin Abs will be categorized as: &lt; 25 percentile: Low, &gt;26 &lt; 75 percentiles: Intermediate, &gt;76 &lt;90 percentiles: High, &gt;91 percentile: Very high.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of asymptomatic carrier of Clostridium difficile in patients with IBD</measure>
    <time_frame>0 days</time_frame>
    <description>Stool testing for C. difficile as part of a multiple step algorithm: GDH (glutamate dehydrogenase), toxin EIA (enzyme immunoassay) test and C. difficile culture.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study the relationship between the different maintenance therapies for IBD and C. difficile anti-toxin Abs and asymptomatic carriers.</measure>
    <time_frame>0 days</time_frame>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Clostridium Difficile</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Non immunosuppressed patients</arm_group_label>
    <description>without treatment or treated with Salicylates and that have not received immunosuppressive therapy, steroids, or biologics in the last 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with immunosuppressive therapy</arm_group_label>
    <description>Azathioprine, 6-Mercaptopurine, Methotrexate in standard dosage at least the past 6 months and that have not received steroids or biologics in the last 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with biologic agents</arm_group_label>
    <description>in standard dosage at least the past 6 months and that have not received steroids in the previous 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with steroid treatment</arm_group_label>
    <description>Must have received daily steroid treatment ≥ 20 mg for ≥ 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>A healthy subject is defined as not having and immunosuppressive underlying condition, not receiving immunosuppressive therapy, has not received antibiotic treatment in the last 6 months, has no past C. difficile infections and has not been in contact with the health care system or hospitalized in the previous 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Determination of serum anti-toxin Abs for C. difficile</intervention_name>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Non immunosuppressed patients</arm_group_label>
    <arm_group_label>Patients with biologic agents</arm_group_label>
    <arm_group_label>Patients with immunosuppressive therapy</arm_group_label>
    <arm_group_label>Patients with steroid treatment</arm_group_label>
    <other_name>Stool culture for C. difficile</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study would include 400 patients with IBD (Crohn's disease and ulcerative colitis).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Diagnosed of IBD, either Crohn's disease or ulcerative colitis

          -  Age: &gt;18 and &lt;65 years

          -  Time since diagnoses of IBD ≥ 6 months

          -  Present with the criteria included in any of the 4 specified groups in the study
             population

        Exclusion Criteria:

          -  History of documented CDI

          -  Active CDI at the moment of study inclusion

          -  Any of the following immunosuppressive conditions: HIV infection, Liver cirrhosis, CKD
             stage IV, Receiving chemotherapy, Transplant (solid organ or hematological),
             Concomitant neoplasia, Hypogammaglobinemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Guardiola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clàudia Arajol, MD</last_name>
    <phone>+34932607500</phone>
    <phone_ext>8091</phone_ext>
    <email>carajol@bellvitgehospital.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Arajol, MD</last_name>
      <email>carajol@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Claudia Arajol Gonzalez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antitoxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

